159 related articles for article (PubMed ID: 29664232)
1. Correlation of TET2 SNP rs2454206 with improved survival in children with acute myeloid leukemia featuring intermediate-risk cytogenetics.
Wang X; Chen X; Yang Z; Dou H; Lu L; Bi J; Zou L; Yu J; Bao L
Genes Chromosomes Cancer; 2018 Aug; 57(8):379-386. PubMed ID: 29664232
[TBL] [Abstract][Full Text] [Related]
2. [Analysis of the Effect of TET2 Mutation and SNP on Clinical Characteristics and Prognosis of AML Patients].
Li L; An LC; Chu XX; Liu XQ; Wang L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):453-459. PubMed ID: 32319378
[TBL] [Abstract][Full Text] [Related]
3. Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.
Kutny MA; Alonzo TA; Gamazon ER; Gerbing RB; Geraghty D; Lange B; Heerema NA; Sung L; Aplenc R; Franklin J; Raimondi SC; Hirsch BA; Konkashbaev A; Cox NJ; Onel K; Gamis AS; Meshinchi S
Leukemia; 2015 Dec; 29(12):2424-6. PubMed ID: 26126966
[No Abstract] [Full Text] [Related]
4. TET2 mutation is an unfavorable prognostic factor in acute myeloid leukemia patients with intermediate-risk cytogenetics.
Chou WC; Chou SC; Liu CY; Chen CY; Hou HA; Kuo YY; Lee MC; Ko BS; Tang JL; Yao M; Tsay W; Wu SJ; Huang SY; Hsu SC; Chen YC; Chang YC; Kuo YY; Kuo KT; Lee FY; Liu MC; Liu CW; Tseng MH; Huang CF; Tien HF
Blood; 2011 Oct; 118(14):3803-10. PubMed ID: 21828143
[TBL] [Abstract][Full Text] [Related]
5. TET2 exon 2 skipping is an independent favorable prognostic factor for cytogenetically normal acute myelogenous leukemia (AML): TET2 exon 2 skipping in AML.
Mohamed AM; Balsat M; Koering C; Maucort-Boulch D; Boissel N; Payen-Gay L; Cheok M; Mortada H; Auboeuf D; Pinatel C; El-Hamri M; Tigaud I; Hayette S; Dumontet C; Cros E; Flandrin-Gresta P; Nibourel O; Preudhomme C; Thomas X; Nicolini FE; Solly F; Guyotat D; Campos L; Michallet M; Ceraulo A; Mortreux F; Wattel E
Leuk Res; 2017 May; 56():21-28. PubMed ID: 28167452
[TBL] [Abstract][Full Text] [Related]
6. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
7. The prognostic impact of tet oncogene family member 2 mutations in patients with acute myeloid leukemia: a systematic-review and meta-analysis.
Wang R; Gao X; Yu L
BMC Cancer; 2019 Apr; 19(1):389. PubMed ID: 31023266
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of TET2 gene expression in 157 adult acute myeloid leukemia patients with normal cytogenetics].
Zhu Z; Chen J; Yu M; Chen F; Chen Z; Lou J; Tong H; Huang J; Qian W; Meng H; Jin J
Zhonghua Xue Ye Xue Za Zhi; 2014 Sep; 35(9):802-7. PubMed ID: 25246247
[TBL] [Abstract][Full Text] [Related]
9. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
10. Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract][Full Text] [Related]
11. Tet oncogene family member 2 gene alterations in childhood acute myeloid leukemia.
Li MJ; Yang YL; Lee NC; Jou ST; Lu MY; Chang HH; Lin KH; Peng CT; Lin DT
J Formos Med Assoc; 2016 Sep; 115(9):801-6. PubMed ID: 26414667
[TBL] [Abstract][Full Text] [Related]
12. TET2 Single Nucleotide Polymorphism in Myeloid Neoplasms Among Egyptian Patients.
Dammag EA; Hamed NAM; Elhalawani NA; Kassem HS; Ayad MW
Indian J Hematol Blood Transfus; 2020 Jan; 36(1):91-96. PubMed ID: 32158090
[TBL] [Abstract][Full Text] [Related]
13. Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial.
Aslanyan MG; Kroeze LI; Langemeijer SM; Koorenhof-Scheele TN; Massop M; van Hoogen P; Stevens-Linders E; van de Locht LT; Tönnissen E; van der Heijden A; da Silva-Coelho P; Cilloni D; Saglio G; Marie JP; Tang R; Labar B; Amadori S; Muus P; Willemze R; Marijt EW; de Witte T; van der Reijden BA; Suciu S; Jansen JH
Ann Hematol; 2014 Aug; 93(8):1401-12. PubMed ID: 24994606
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of Tet methylcytosine dioxygenase 2 (TET2) gene mutations in adult patients with acute myeloid leukemia: a meta-analysis.
Liu WJ; Tan XH; Luo XP; Guo BP; Wei ZJ; Ke Q; He S; Cen H
Leuk Lymphoma; 2014 Dec; 55(12):2691-8. PubMed ID: 24524305
[TBL] [Abstract][Full Text] [Related]
15. Landscape of TET2 mutations in acute myeloid leukemia.
Weissmann S; Alpermann T; Grossmann V; Kowarsch A; Nadarajah N; Eder C; Dicker F; Fasan A; Haferlach C; Haferlach T; Kern W; Schnittger S; Kohlmann A
Leukemia; 2012 May; 26(5):934-42. PubMed ID: 22116554
[TBL] [Abstract][Full Text] [Related]
16. 5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia.
Ahn JS; Kim HJ; Kim YK; Lee SS; Ahn SY; Jung SH; Yang DH; Lee JJ; Park HJ; Choi SH; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Kim SH; Michael S; Minden MD; Kim DD
Oncotarget; 2017 Jan; 8(5):8305-8314. PubMed ID: 28039446
[TBL] [Abstract][Full Text] [Related]
17. Hyperleukocytosis is associated with distinct genetic alterations and is an independent poor-risk factor in de novo acute myeloid leukemia patients.
Tien FM; Hou HA; Tsai CH; Tang JL; Chen CY; Kuo YY; Li CC; Lin CT; Yao M; Huang SY; Ko BS; Hsu SC; Wu SJ; Tsay W; Tseng MH; Liu MC; Liu CW; Lin LI; Chou WC; Tien HF
Eur J Haematol; 2018 Jul; 101(1):86-94. PubMed ID: 29624746
[TBL] [Abstract][Full Text] [Related]
18. TET2 expression is a potential prognostic and predictive biomarker in cytogenetically normal acute myeloid leukemia.
Zhang TJ; Zhou JD; Yang DQ; Wang YX; Wen XM; Guo H; Yang L; Lian XY; Lin J; Qian J
J Cell Physiol; 2018 Aug; 233(8):5838-5846. PubMed ID: 29219176
[TBL] [Abstract][Full Text] [Related]
19. A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.
Sloan CE; Luskin MR; Boccuti AM; Sehgal AR; Zhao J; Daber RD; Morrissette JJ; Luger SM; Bagg A; Gimotty PA; Carroll M
PLoS One; 2016; 11(4):e0153016. PubMed ID: 27050425
[TBL] [Abstract][Full Text] [Related]
20. TET2 gene mutation is unfavorable prognostic factor in cytogenetically normal acute myeloid leukemia patients with NPM1+ and FLT3-ITD - mutations.
Tian X; Xu Y; Yin J; Tian H; Chen S; Wu D; Sun A
Int J Hematol; 2014 Jul; 100(1):96-104. PubMed ID: 24859829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]